Prospective Randomized Group Controlled Study of Clinical Efficacy and Safety of the CE marked Vertidisan® App

Prospective Randomized Group Controlled Study of Clinical Efficacy and Safety of the CE marked Vertidisan® App - RCT VH-90-D

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00024188

Enrollment

200

Registered

2022-10-06

Start date

2022-10-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H81.0 H81.1 H81.2 H81.3 H81.8 H81.9 R29.6

Interventions

Group 1: During 12 weeks: BEV (adaptive Balance movements, Eye-movements and Visual stimulation exercises), (ii) health education (HE) and (iii) CBT (cognitive behavioral therapy), (iv) MC: Medical Co

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: vestibular vertigo

Exclusion criteria

Exclusion criteria: Severe bone disease Severe internal disease Severe neurological disease Central vertigo Severe visual disorder No German language

Design outcomes

Primary

Measure	Time frame
VSS-V-Scale. VSS-sf-VER-questionaire at T0, after 2, 6 and 12 weeks.	—

Secondary

Measure	Time frame
DHI, CGI-I, CGI-S, Stress thermometer, VSS-sf-AA, SF 36	—

Countries

Germany

Contacts

Public ContactHans-Peter Zenner

Clinical Research Organization, HP Zenner Clinical GmbH&CoKG

office@hpzenner.de+49707149645

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 20, 2026